| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Hintikka, E. -L., et al.
(författare)
-
Mycotoxins in the ventilation systems of four schools in Finland
- 2009
-
Ingår i: World Mycotoxin Journal. - 1875-0796. ; 2:4, s. 369-379
-
Tidskriftsartikel (refereegranskat)abstract
- Some fungal species have been listed as a problem causing fungi in indoor air and most of this group are known to produce mycotoxins. So far, mycotoxins have been found in building materials and in samples representing settled indoor air dust, as well in air samples from industrial or agricultural environments. The present paper presents the results of a mycological study and mycotoxin analyses of dust collected from mechanical ventilation systems in four school buildings in southern Finland. The aim of this work was to answer the question 'Are there mycotoxins in ventilation systems and if so, from where do they originate?' A total of 40 mycotoxins representing indoor and outdoor sources alike were screened in this study, while cultivable fungi were screened using four different cultivation media. Mycotoxins were present in all ventilation systems studied, both in the supply and the exhaust systems examined. The mycotoxins found included satratoxins, verrucarol, trichodermol, enniatins, beauvericin, penicillic acid, sterigmatocystin, chaetoglobosin A, and aflatoxins B-1. The mycotoxins were present in minute quantities (pg-ng/g or pg-ng/cm(2)). The fungal genera associated with respective mycotoxins were found in most of the same sources. Since much the same mycotoxins could be established in both exhaust and supply air systems, it would appear that the mycotoxins found in the schools studied do not for the most part originate from sources within the building but are either normal artefacts of incoming supply air or concentrate or are perhaps produced within the ventilation systems due to infrequent changing of filters and maintenance/cleaning of ventilation ducts and associated parts of the systems.
|
|
| 5. |
- Kellokumpu-Lehtinen, PLI, et al.
(författare)
-
Triweekly docetaxel versus biweekly docetaxel as a treatment for advanced castration resistant prostate cancer: Quality of life analysis
- 2014
-
Ingår i: JOURNAL OF CLINICAL ONCOLOGY. - : American Society of Clinical Oncology (ASCO). - 0732-183X .- 1527-7755. ; 32:4
-
Konferensbidrag (övrigt vetenskapligt/konstnärligt)abstract
- 23 Background: Bi-weekly docetaxel (T) with prednisone improved progression free survival and overall survival when compared with the standard tri-weekly T as first-line treatment for advanced castration resistant prostate cancer (CRPC) (Lancet Oncol. 2013;14:117-124). We report here the quality of life (QoL) results of this prospective randomized trial. Methods: Three hundred and forty-six patients were randomly allocated centrally to receive intravenous therapy T of either 75 mg/m² d1 q3 wks (the triweekly arm) or 50 mg/m² d1 and d 14, q4 wks (the biweekly arm) (identifier NCT00255606). Prednisone (10 mg/d) was administered orally in both groups. The baseline patients characteristics were well balanced between the groups with respect to the performance status, mean age (69, range 45 to 87 vs. 68, range 46 to 85), and median serum prostate-specific antigen (PSA) content (109 µg/L, range 11 to 1,230 vs. 116 µg/L, range 12 to 1,870). Quality of life (QoL), the frequency and severity of symptoms including pain were assessed using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) version 4.0 questionnaire. Results: The baseline (QoL) of both treatment groups was compared to QoL after six months of the treatment within each treatment group and between groups. Changes in fatigue, symptoms of pain and nausea, and the overall performance status did not differ between the groups. There were statistically significant differences in overall quality of life values (p=0.010) and discomforting pain values (p=0.028) favoring the bi-weekly treatment arm. Conclusions: Bi-weekly T is better tolerated than the tri-weekly standard T. Following the results from the clinical outcome and the QoL outcome in the PROSTY trial we would recommend the use of bi-weekly docetaxel as first line treatment of CRPC Clinical trial information: NCT00255606.
|
|
